Debiopharm
Debiopharm Group, a Swiss biopharmaceutical company headquartered in Lausanne, Switzerland (CH), has been a key player in the pharmaceutical industry since its founding in 1971. Specialising in the development of innovative therapies for oncology and infectious diseases, Debiopharm focuses on advancing drug development through its robust pipeline and strategic partnerships. With a commitment to improving patient outcomes, the company offers unique products that leverage cutting-edge technology and research. Notable achievements include the successful launch of several targeted therapies that have significantly impacted cancer treatment. Debiopharm's strong market position is underscored by its dedication to quality and innovation, making it a respected name in the global biopharmaceutical landscape.
DitchCarbon Score
How does Debiopharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Debiopharm's score of 6 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Debiopharm's reported carbon emissions
In 2021, Debiopharm reported greenhouse gas emissions with a focus on Scope 1 and 2 emissions, achieving an intensity of approximately 0.09 kg CO2e per unit of revenue. However, specific total emissions figures were not disclosed. The company has not set any formal reduction targets or climate pledges, indicating a potential area for future commitment in addressing climate change. As a pharmaceutical company headquartered in Switzerland (CH), Debiopharm is positioned within an industry increasingly scrutinised for its environmental impact, highlighting the importance of transparent climate strategies and measurable emissions reductions.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Debiopharm is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
